KNSA icon

Kiniksa Pharmaceuticals

96 hedge funds and large institutions have $306M invested in Kiniksa Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 36 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

more call options, than puts

Call options by funds: $ | Put options by funds: $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more ownership

Funds ownership:

less funds holding

Funds holding:

12% less capital invested

Capital invested by funds: $346M → $306M (-$40.3M)

35% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 20

Holders
96
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$2.44M
Puts
$1.77M
Net Calls
Net Calls Change

Top Buyers

1 +$5.78M
2 +$4.97M
3 +$4.58M
4
LPC
Lion Point Capital
New York
+$4.22M
5
Goldman Sachs
Goldman Sachs
New York
+$3.55M

Top Sellers

1 -$8.93M
2 -$2.87M
3 -$2.81M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.44M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
26
$1.7M
27
$1.58M
28
$1.36M
29
$1.18M
30
$1.14M
31
$1.01M
32
$966K
33
$815K
34
$772K
35
$767K
36
$710K
37
$659K
38
$651K
39
$649K
40
$608K
41
$597K
42
$585K
43
$524K
44
$470K
45
$428K
46
$421K
47
$374K
48
$369K
49
$353K
50
$352K